0.00Open0.04Pre Close0 Volume13 Open Interest3.00Strike Price0.00Turnover0.00%IV44.78%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma134.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Verastem Stock Discussion
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
Tuesday, 14th January at 7:30 am
VS-7375 is a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor currently in Phase 1 development in China in advanced KRAS G12D mutant solid tumors; Verastem anticipates filing a U.S. IND application for VS-7375 during Q1 2025 a...
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
Monday, 13th January at 7:30 am
Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma cash position of $128.6 million including debt refinancing and equity issuance provides cash runway beyond FDA approval
Veras...
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review
Big News came out
wow, still rolling, I sold at 4 lol
No comment yet